铁化作为黑色素瘤的有前途的治疗策略
Na Ta1, Xiaodong Jiang2, Yongchun Zhang3
1Department of Neurosurgery, The Affiliated Hospital of Chifeng University, Chifeng, China.
Frontiers in pharmacology
|October 5, 2023
概括
针对细胞死亡过程 - - 铁灭症,显示出治疗恶性黑色素瘤 (MM) 的前景. 诱导铁亡可能为晚期MM提供新的治疗策略,改善患者的预后.
科学领域:
- 在瘤学瘤学.
- 细胞死亡机制 细胞死亡机制
- 皮肤病学 皮肤病学
背景情况:
- 恶性黑色素瘤 (MM) 是一种具有高死亡率的侵袭性皮肤癌.
- 目前的治疗方法效果有限,特别是对于药物耐药性的晚期治疗.
- 铁,一种依赖于铁的细胞死亡,与预防MM发展有关.
研究的目的:
- 审查MM中铁亡的机制.
- 探索铁死作为MM的治疗点.
- 讨论涉及ferroptosis诱导的新型治疗策略.
主要方法:
- 在MM中对铁亡机理的文献综述.
- 针对铁灭途径的小分子的分析.
- 检查纳米医学在基于铁的MM疗法中的应用.
主要成果:
- 诱导ferroptosis可以防止MM的进展.
- 小分子增强了BRAFi的抗瘤活性,并通过ferroptosis进行免疫治疗.
- 纳米敏化剂和纳米药物提供了基于铁灭的向治疗策略.
结论:
- 药理学诱导铁亡是一种有前途的MM治疗策略.
- 向铁死可以克服晚期MM的耐药性.
- 新的纳米医学方法提高了基于铁灭的治疗疗效.
更多相关视频
06:46Ortho- and Ectopic Zebrafish Xeno-Engraftment of Ocular Melanoma to Recapitulate Primary Tumor and Experimental Metastasis Development
Published on: September 4, 2021
1.4K
05:33Author Spotlight: Recreating Melanoma Complexity with Patient-Derived Organoids for Immunotherapy Evaluation
Published on: September 6, 2024
1.5K
相关概念视频
Necrosis
4.6K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
4.6K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Tumor Immunotherapy
544
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
544
